Blog
RSS FeedPosted by Michael Wonder on 02 Nov 2020
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
2 November 2020 - Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for ...
Posted by Michael Wonder on 19 Oct 2020
Bristol Myers Squibb receives positive CHMP opinion recommending Opdivo (nivolumab) as second-line treatment for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
16 October 2020 - Application based on Phase 3 ATTRACTION-3 trial demonstrating a statistically significant and clinically meaningful improvement in patients’ ...
Posted by Michael Wonder on 18 Oct 2020
First CAR-T cell medicine for mantle cell lymphoma
16 October 2020 - EMA has recommended granting a conditional marketing authorisation in the European Union for Tecartus (autologous anti-CD19 ...
Posted by Michael Wonder on 15 Oct 2020
EMA cancer symposium: new approaches in patient-focused cancer medicine development
15 October 2020 - On Thursday, 29 October, EMA is hosting a symposium to discuss new approaches to facilitating and ...
Posted by Michael Wonder on 01 Oct 2020
EMA reminds physicians to use Tecentriq with nab-paclitaxel for treating breast cancer
1 October 2020 - EMA is reminding physicians to use Tecentriq (atezolizumab) only in combination with nab-paclitaxel and not with ...
Posted by Michael Wonder on 28 Sep 2020
Blueprint Medicines announces European Commission approval of Ayvakyt (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastro-intestinal stromal tumours
25 September 2020 - First highly effective treatment option approved in Europe for PDGFRA D842V mutant GIST. ...
Posted by Michael Wonder on 21 Sep 2020
Lynparza recommended for approval in the EU by CHMP for BRCA mutated metastatic castration-resistant prostate cancer
21 September 2020 - Only PARP inhibitor to improve overall survival versus new hormonal agent treatments in advanced prostate cancer. ...
Posted by Michael Wonder on 21 Sep 2020
Lynparza recommended for approval in EU by CHMP as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer
21 September 2020 - Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. ...
Posted by Michael Wonder on 21 Sep 2020
Bristol Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with two cycles of chemotherapy as first-line treatment of metastatic non-small cell lung cancer
18 September 2020 - Application based on results from the Phase 3 CheckMate -9LA trial, which showed significantly improved overall survival ...
Posted by Michael Wonder on 20 Sep 2020
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
18 September 2020 - Recommendation is based on the results of the IMbrave150 study, in which the Tecentriq combination improved overall ...
Posted by Michael Wonder on 16 Sep 2020
EMA validates Bristol Myers Squibb’s type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for first-line treatment of malignant pleural mesothelioma
15 September 2020 - Opdivo plus Yervoy would potentially be the first immunotherapy option for the first-line treatment of this cancer ...
Posted by Michael Wonder on 08 Sep 2020
Janssen announces European Commission decision for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated patients with chronic lymphocytic leukaemia
7 September 2020 - Patients who were new to chronic lymphocytic leukaemia treatment lived longer without disease progression with the Imbruvica ...
Posted by Michael Wonder on 01 Sep 2020
Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer
1 September 2020 - Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit and improved response rate in combination with a ...
Posted by Michael Wonder on 27 Aug 2020
European Commission approves Blenrep (belantamab mafodotin) for the treatment of patients with relapsed and refractory multiple myeloma
26 August 2020 - Marketing authorisation follows the recent US approval of Blenrep. ...
Posted by Michael Wonder on 03 Aug 2020
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
3 August 2020 - Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain. ...